scholarly journals The PARAGON Heart Failure trial – ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction

2019 ◽  
Vol 28 (4) ◽  
pp. 215-216 ◽  
Author(s):  
Sverre E. Kjeldsen ◽  
Krzysztof Narkiewicz ◽  
Michel Burnier ◽  
Suzanne Oparil
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Receptor Antagonist ◽  
Preserved Ejection Fraction ◽  
Angiotensin Receptor ◽  
Angiotensin Receptor Antagonist ◽  
Heart Failure Patients ◽  
Heart Failure Trial ◽  
Neprilysin Inhibitor

Sacubitril/Valsartan: potential treatment for paediatric heart failure

2018 ◽  
Vol 28 (9) ◽  
pp. 1077-1081 ◽  
Author(s):  
Bibhuti B. Das ◽  
Frank Scholl ◽  
Breanna Vandale ◽  
Maryanne Chrisant
Keyword(s):  
Heart Failure ◽  
Potential Role ◽  
Enzyme Inhibitor ◽  
Angiotensin Receptor ◽  
Mortality And Morbidity ◽  
Heart Failure Patients ◽  
Heart Failure Trial ◽  
Prospective Comparison ◽  
Neprilysin Inhibitor

AbstractThe Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.

Sign in / Sign up

Export Citation Format

Share Document